Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01546363|
Recruitment Status : Recruiting
First Posted : March 7, 2012
Last Update Posted : May 9, 2017
|Condition or disease||Intervention/treatment|
|Cervical Cancer||Other: Blood draw|
SPECIFIC STUDY AIMS
Specific Aim 1: To use gene expression analysis of primary cervical cancers to identify a gene expression signature that predicts for lymph node metastases in this disease.
Specific Aim 2: To predict lymph node metastases by performing multiplex measurements of cancer-associated proteins and cytokines using proximity ligation assay (PLA) on plasma samples.
Specific Aim 3: To measure circulating human papilloma virus (HPV) DNA in the plasma samples of cervical cancer patients using real-time quantitative polymerase chain reaction (qPCR) and determine its ability to predict for nodal metastases.
Specific Aim 4: To use deep sequencing to evaluate gene and sequence differences between cervical cancer patients with and without lymph node metastasis.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer|
|Study Start Date :||February 2012|
|Estimated Primary Completion Date :||January 1, 2019|
|Estimated Study Completion Date :||January 1, 2019|
Other: Blood draw
Other: Blood draw
- Biomarkers (genes and proteins) of lymph node involvement [ Time Frame: 4 years ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01546363
|Contact: Dylann Fujimotofirstname.lastname@example.org|
|United States, California|
|Stanford University, School of Medicine||Recruiting|
|Stanford, California, United States, 94305|
|Contact: Dylann Fujimoto 650-723-8843 email@example.com|
|Sub-Investigator: Albert Koong, MD|
|Principal Investigator:||Elizabeth Kidd, MD||Stanford University|